Novavax (NVAX) Interest Expenses (2010 - 2026)

Novavax's Interest Expenses history runs 17 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 9.98% year-over-year to $6.3 million in Q1 2026; TTM through Mar 2026 was $28.0 million, a 59.63% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 9.67% from the prior year.
• Interest Expenses slipped to $6.3 million in Q1 2026 per NVAX's latest filing, from $10.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $174.9 million in Q4 2022 and bottomed at $2.9 million in Q3 2023.
• The 5-year median for Interest Expenses is $5.7 million (2025), against an average of $18.4 million.
• Across the five-year window, Interest Expenses sank 96.84% in 2023 and jumped 897.16% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $174.9 million in 2022, then sank by 96.84% to $5.5 million in 2023, then soared by 897.16% to $55.2 million in 2024, then sank by 81.09% to $10.4 million in 2025, then slumped by 39.68% to $6.3 million in 2026.
• Per Business Quant, the three latest NVAX Interest Expenses figures stand at $6.3 million (Q1 2026), $10.4 million (Q4 2025), and $7.6 million (Q3 2025).